intravitreal injection with ranibizumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pigment Epithelial Detachment
Conditions
Pigment Epithelial Detachment
Trial Timeline
Dec 1, 2008 → Dec 1, 2015
NCT ID
NCT00976222About intravitreal injection with ranibizumab
intravitreal injection with ranibizumab is a approved stage product being developed by Novartis for Pigment Epithelial Detachment. The current trial status is completed. This product is registered under clinical trial identifier NCT00976222. Target conditions include Pigment Epithelial Detachment.
What happened to similar drugs?
2 of 3 similar drugs in Pigment Epithelial Detachment were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00976222 | Approved | Completed |
Competing Products
20 competing products in Pigment Epithelial Detachment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib + Placebo | Daiichi Sankyo | Phase 3 | 40 |
| DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3 | Sumitomo Pharma | Phase 1/2 | 39 |
| AGN-151597 | AbbVie | Phase 1/2 | 32 |
| nilotinib | Novartis | Phase 2 | 35 |
| MCS110 + Placebo | Novartis | Phase 2 | 35 |
| CPK850 | Novartis | Phase 1/2 | 36 |
| Ranibizumab | Novartis | Phase 2 | 35 |
| iSONEP (sonepcizumab/LT1009) | Pfizer | Phase 1 | 21 |
| Aflibercept | Regeneron Pharmaceuticals | Approved | 35 |
| Aflibercept | Regeneron Pharmaceuticals | Approved | 43 |
| BIIB112 | Biogen | Phase 1/2 | 29 |
| OCU400 | Ocugen | Pre-clinical | 24 |
| OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye Dosing | Ocugen | Phase 1/2 | 30 |
| 4D-125 IVT Injection | 4D Molecular Therapeutics | Phase 1/2 | 30 |
| Afamelanotide | Clinuvel Pharmaceuticals | Phase 2 | 25 |
| Afamelanotide | Clinuvel Pharmaceuticals | Phase 2 | 25 |
| QR-1123 | ProQR | Phase 1/2 | 26 |
| QR-421a | ProQR | Phase 1/2 | 22 |
| ADX-2191 + ADX-2191 | Aldeyra Therapeutics | Phase 2 | 25 |
| BS01 | Bionic Sight | Phase 1/2 | 29 |